Neomay 500 000 IU/g Powder for Use in Drinking Water/Milk Replacer

Šalis: Didžioji Britanija

kalba: anglų

Šaltinis: VMD (Veterinary Medicines Directorate)

Veiklioji medžiaga:

Neomycin

Prieinama:

Laboratorios Maymo S.A.

ATC kodas:

QA07AA01

INN (Tarptautinis Pavadinimas):

Neomycin

Vaisto forma:

Powder for use in drinking water/milk

Recepto tipas:

POM-V - Prescription Only Medicine – Veterinarian

Farmakoterapinė grupė:

Cattle, Chickens, Duck, Goose, Partridge, Pigs, Quail, Turkeys

Gydymo sritis:

Antimicrobial

Autorizacija statusas:

Authorized

Leidimo data:

2017-01-09

Prekės savybės

Revised: October 2020
AN: 02122/2019
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
NEOMAY 500 000 IU/g powder for use in drinking water/milk replacer
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each g contains:
ACTIVE SUBSTANCE:
Neomycin (as neomycin sulphate)500 000 IU
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for use in drinking water/milk replacer.
White or almost white powder.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (calves), pigs (weaned and fattening pigs), chickens (including
laying hens),
ducks, turkeys (including turkey hens), geese, quail and partridges.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For treatment of gastrointestinal infections caused by _E. coli_
susceptible to neomycin.
4.3
CONTRAINDICATIONS
Do
not
use
in
known
cases
of
hypersensitivity
to
the
active
substance,
to
aminoglycosides or to any of the excipients.
Do not use in cases of intestinal obstruction.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Medicated drinking water intake can be affected by the severity of the
disease. In
case of insufficient intake of water/milk replacer, calves and pigs
should be treated
parenterally.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Powder for oral solution that is to be dissolved in water and cannot
be used as it is.
Special care should be taken when considering administration of the
product to the
newborn calf due to the known higher gastrointestinal absorption of
neomycin in
neonates.
This
higher
absorption
could
lead
to
an
increased
risk
of
oto-
and
nephrotoxicity.
The
use
of
the
product
in
neonates
should
be
based
on
the
benefit/risk determination from the attending veterinarian.
Revised: October 2020
AN: 02122/2019
Page 2 of 5
Use of the product should be based on susceptibility testing of the
bacteria isolated
from the animal. If this is not possible, therapy should be based on
local (regional,
farm level) epidemiological information about susceptibili